Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACCESS-1: Pozelimab + cemdisiran versus ravulizumab or eculizumab in PNH
jRCT2031220440Active, not recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
Randomised, open-label trial of pozelimab, cemdisiran, ravulizumab and eculizumab in paroxysmal nocturnal hemoglobinuria (PNH) (4 cohorts), sponsored by Regeneron Pharmaceuticals. Started Jun 2023; status: active, not recruiting.
02
Drugs
pozelimabcemdisiranravulizumabeculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2031220440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220440.